Trial · NCT03350451
Adverse events216
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 216
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lymphadenopathy | Blood and lymphatic system disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Atrioventricular Block | Cardiac disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Atrioventricular Block | Cardiac disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 0 | 7 | |
| other | Ear Pain | Ear and labyrinth disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 0 | 13 | |
| other | Ear Pain | Ear and labyrinth disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Hyperacusis | Ear and labyrinth disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Hyperacusis | Ear and labyrinth disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 0 | 7 | |
| other | Hypoacusis | Ear and labyrinth disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 0 | 13 | |
| other | Hypoacusis | Ear and labyrinth disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Thyroid Mass | Endocrine disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 0 | 13 | |
| other | Thyroid Mass | Endocrine disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Eye Allergy | Eye disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Eye Allergy | Eye disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 0 | 7 | |
| other | Periorbital Swelling | Eye disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 0 | 13 | |
| other | Periorbital Swelling | Eye disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Abdominal Discomfort | Gastrointestinal disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 0 | 13 | |
| other | Abdominal Discomfort | Gastrointestinal disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 | |
| other | Abdominal Pain | Gastrointestinal disorders | Lumasiran (ALN-GO1): 1.0 mg/kg QM or 3.0 mg/kg Q3M | 1 | 13 | |
| other | Abdominal Pain | Gastrointestinal disorders | Lumasiran (ALN-GO1): 3.0 mg/kg QM | 1 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03350451/events